Thursday, 23 Jan 2020

You are here

Legionella Outbreak in NYC

An outbreak of Legionnaires' disease has killed four people and sickened 65 in the Bronx section of New York City since July 10, according to New York City health officials. This Legionnaires' outbreak is now more than five times the number of cases recorded in the last outbreak, in which 12 people in the Bronx fell ill in December 2014.

Legionella is a bacteria that can be found in certain plumbing systems, including hot tubs, humidifiers, cooling towers and hot water tanks. It is spread by breathing in mist from water, and cannot be spread from person to person. It is most common in the summer and early fall, according to the Centers for Disease Control and Prevention. 

In 2011 the FDA added Legionella to the boxed warnings on all TNF inhibitors based on their review of 80 reports of Legionella pneumonia in patients receiving TNF inhibitors (TNFI); 14 patients died. The median age of patients was 56 years (range 25-85 years). The most frequent indication for TNFi use was RA (65%) and the mean duration of use 10.4 months (range < 1-73 months). Many patients were also on methotrexate, steroids, or both. Legionnaires' disease is a systemic infectious disease primarily involving the lungs. Patients often present with fever, cough, headaches and muscle aches, and extrapulmonary manifestations (e.g., FUO, serositis, endocarditis, myocarditis, pyelonephritis, abscesses) are not uncommon. 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Best of 2019 - Biologic Safety Guidelines from the British Society for Rheumatology

In the United Kingdom, NICE has looked to the British Society of Rheumatology (BSR) to develop evidence based guidance on the safe use of biologic DMARDs in patients with inflammatory arthritis. This guidance document on biologic safety covers baseline screening, monitoring, effect of co-morbidities, and when or under what circumstances biologic therapy should be interrupted.

Best of 2019 - Methotrexate and the Risk of Lung Disease

Rheumatology has a comprehensive overview of methotrexate (MTX) and the risk of lung injury, MTX-related pneumonitis and interstitial lung disease (RA-ILD) with rheumatoid arthritis (RA). Past reports suggest the frequence of MTX-pneumonitis to be between 0.3 and 11.6%; recent studies suggest it may be much lower.

No Cancer Risk with Systemic Necrotizing Vasculitis

The French Vasculitis Study Group has published that patients with systemic necrotizing vasculitis do not have an increased risk of malignancy; in fact they have a risk that is similar to the general population.

Previous reports have suggested either no risk or a declining risk in the era of better therapies for vasculitis. 

FDA Warns 15 CBD Manufacturers

Today, the U.S. Food and Drug Administration issued warning letters to 15 companies for illegally selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act).  This warning affirms that the FDA has not determined the many preparations of cannabidiol to be safe or effective.

Biologic Safety Guidelines from the British Society for Rheumatology

In the United Kingdom, NICE has looked to the British Society of Rheumatology (BSR) to develop evidence based guidance on the safe use of biologic DMARDs in patients with inflammatory arthritis. This guidance document on biologic safety covers baseline screening, monitoring, effect of co-morbidities, and when or under what circumstances biologic therapy should be interrupted.